KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Wall Street analysts forecast KYMR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kymera Therapeutics Inc revenue for the last quarter amounts to 2.76M USD, decreased -26.12 % YoY.

Kymera Therapeutics Inc. EPS for the last quarter amounts to -0.94 USD, increased 14.63 % YoY.

Kymera Therapeutics Inc (KYMR) has 188 emplpoyees as of December 15 2025.

Today KYMR has the market capitalization of 7.08B USD.